-

Fresenius Kabi Named 2023 Supplier Partner of the Year by Vizient

Recognition Based on Commitment to Collaboration, Quality and Service

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi has been named the 2023 Supplier Partner of the Year by Vizient, Inc., the nation’s largest provider-driven health care performance improvement company. The recognition was celebrated September 18-21 at the 2023 Vizient Connections Summit in Las Vegas.

#FreseniusKabi has been named the 2023 Supplier Partner of the Year by @VizientInc, the nation’s largest provider-driven #healthcare performance improvement company.

Share

According to Vizient, the Supplier Partner of the Year demonstrates an unmatched willingness to improve performance and deliver on Vizient’s mission to strengthen Vizient provider customers’ delivery of high-value care. With actively engaged senior executives, the Supplier Partner of the Year provides comprehensive contract access across product/service lines and participates widely in performance improvement solutions and programs, proactively engaging the broader Vizient enterprise and bringing high-value solutions to unmet market needs.

“This recognition as Vizient’s Supplier Partner of the Year reflects our team’s commitment to collaboration and innovation to enhance quality of care and patient safety while controlling costs,” said Scott Meacham, president, Pharmaceuticals at Fresenius Kabi USA. “At every level of our organization, we are focused on helping customers find new solutions for meeting the challenges of today’s health care environment.”

The award marks the second time Fresenius Kabi has been named Supplier Partner of the Year since 2016. In addition, Fresenius Kabi has been named Vizient’s Pharmaceutical Partner of the Year three times, and twice as the Vizient Strategic Programs Pharmaceutical Supplier of the Year in this time period.

“We are excited to recognize Fresenius Kabi as this year’s winner of the prestigious Supplier Partner of the Year Award. Fresenius Kabi has demonstrated how suppliers can work differently with Vizient to ensure that together we are delivering on our provider customer’s holistic needs relative to cost, quality, and market performance. They have also shown exemplary commitment to quality and service, putting providers and the patients they care for at the center of all they do,” said Simrit Sandhu, executive vice president, clinical supply solutions, Vizient.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in injectable medicines, biosimilars, and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for patients with critical and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

Contacts

Joanie Clougherty, 614-717-5741
joan.clougherty@fresenius-kabi.com

Fresenius Kabi


Release Versions

Contacts

Joanie Clougherty, 614-717-5741
joan.clougherty@fresenius-kabi.com

Social Media Profiles
More News From Fresenius Kabi

Fresenius Kabi and AABB Announce 21st Annual Blood Collectors Week, September 6–12, 2026, Honoring Lifesaving Blood Collection Professionals

LAKE ZURICH, Ill. & BETHESDA, Md.--(BUSINESS WIRE)--Fresenius Kabi and the Association for the Advancement of Blood & Biotherapies (AABB) announced today the launch of the 21st annual Blood Collectors Week, taking place September 6–12, 2026. The annual recognition week celebrates the blood collection professionals whose expertise and dedication help ensure patients across the country have access to safe, high-quality blood and blood components. Blood Collectors Week honors the essential pro...

Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S.

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, a global healthcare company part of the Fresenius Group, specializing in lifesaving therapies and technologies, today announced the U.S. launch of the FDA‑approved generic Sugammadex Injection. Exclusivity for the branded medicine Bridion® (Merck) expired in July 2026. Fresenius Kabi offers operating room clinicians Sugammadex in a Simplist® ready-to-administer prefilled syringe. Simplist® single-dose, prefilled syringes require no assembly at...

Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles. Risk Statement: The administration of an injectable product containing glass particulates may cause local irritation, pain, or swelling at the infusion site, as well as inflammation of the veins. More se...
Back to Newsroom